Metastasis of renal cell carcinoma to haemangioblastoma of the spinal cord in von Hippel-Lindau disease: Case report and review of the literature

Pathology

Volumn 35, Issue 3, 2003, Pages 224-227

  Abou Hamden, Amal ^c   Koszyca, Barbara ^a   Carney, Paul G ^c   Sandhu, Nindi ^c   Blumbergs, Peter C ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^c NONE

Author keywords

Haemangioblastoma; Renal cell carcinoma; Spinal cord metastasis; Von Hippel Lindau disease

Indexed keywords

ADULT; ARTICLE; CASE REPORT; DISEASE COURSE; HEMANGIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY CARCINOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SPINAL CORD METASTASIS; SYMPTOMATOLOGY; VON HIPPEL LINDAU DISEASE;

EID: 0038163882     PISSN: 00313025     EISSN: None     Source Type: Journal    
DOI: 10.1080/003130203100023191     Document Type: Article

References (30)

1. McLendon RE, Tien RD. Russell and Rubinstein's Pathology of Tumours of the Nervous System. Vol. 2.6th ed. London: Arnold, 1998; Chapter 16, Genetic syndromes associated with tumors and/or hamartomas.
2. Conway JE, Chou D, Clatterbuck RE, et al. Hemangioblastomas of the central nervous system in von Hippel-Lindau syndrome and sporadic disease. Neurosurgery 2001; 48: 55-63.
3. McEvoy AW, Benjamin E, Powell MP. Haemangioblastoma of a cervical sensory nerve root in von Hippel-Lindau syndrome. Eur Spine J 2000; 9: 434-6.
4. Bret P, Streichenberger N, Guyotat J. Metastasis of renal cell carcinoma to a cerebellar haemangioblastoma in a patient with von Hippel-Lindau disease: a case report. Br J Neurosurg 1999; 13: 413-6.
5. Crockard HA, Barnard RO, Isaacson PG. Metastasis of carcinoma to hemangioblastoma cerebelli: case report. Neurosurgery 1988; 23: 382-4.
6. Jamjoon A, Kane N, Nicoll J. Metastasis of a renal cell carcinoma to a cerebellar hemangioblastoma in a case of von Hippel-Lindau disease. Neurosurg Rev 1992; 15: 231-4.
7. Chacko AG, Rajshekar V, Chacko G. Testicular embryonal carcinoma metastasising to the site of a previously excised cerebellar hemangioblastoma. Br J Neurosurg 1996; 10: 194-200.
8. Schmitt HP. Metastases of malignant neoplasms to intracranial tumours: the 'tumour-in-a-tumour' phenomenon. Virchows Arch 1984; 405: 155-60.
9. Conzen M, Sollmann H, Schnabel R. Metastasis of lung carcinoma to intracranial meningioma. Case report and review of the literature. Neurochirurgia 1986; 29: 206-9.
10. Pamphlett R. Carcinoma metastasis to meningioma. J Neurol Neurosurg Psychiatry 1984; 47: 561-3.
11. Andrew SM, Gradwell E. Immunoperoxidase labelled antibody staining in differential diagnosis of central nervous system haemangioblastomas and central nervous system metastases of renal carcinomas. J Clin Pathol 1986; 39: 917-9.
12. Clelland CA, Treip CS. Histological differentiation of metastatic renal cell carcinoma of the cerebellum from cerebellar haemangioblastoma in von Hippel-Lindau's disease. J Neurol Neurosurg Psychiatry 1989; 52: 162-6.
13. Gouldsborough DR, Bell JE, Gordon A. Use of immunohistochemical methods in the differential diagnosis between primary cerebellar haemangioblastoma and metastatic renal carcinoma. J Clin Pathol 1988; 41: 861-5.
14. Mills SE, Ross GW, Perentes E, et al. Cerebellar hemangioblastoma: immunohistochemical distinction from metastatic renal cell carcinoma. Surg Pathol 1990; 3: 121-32.
15. Decker HJH, Weidt EJ, Brieger J. The von Hippel-Lindau tumour suppressor gene. Cancer Genet Cytogenet 1997; 93: 74-83.
16. Richards FM, Webster AR, McMahon R, et al. Molecular genetic analysis of von Hippel-Lindau disease. J Intern Med 1998; 243: 527-33.
17. Shui T, Kondo K, Torigoe S, et al. Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary renal cell carcinomas. Cancer Res 1994; 54: 2852-5.
18. Ohh M, Kaelin WG. The von Hippel-Lindau tumor suppressor protein: new perspectives. Mol Med Today 1999; 5: 257-63.
19. Iliopolous O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996; 93: 10 595-9.
20. Gnarra JR, Zhou S, Merril MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci USA 1996; 93: 10 589-94.
21. Krieg M, Marti HH, Plate KH. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 1998; 92: 3388-93.
22. Yu F, White SB, Zhao Q, et al. Dynamic site specific interaction of hypoxia inducible factor 1α with the von Hippel-Lindau tumor suppressor protein. Cancer Res 2001; 61: 4136-42.
23. Tanimoto K, Makino Y, Pereira T, et al. Mechanism of regulation of the hypoxia-inducible factor 1α by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000; 19: 4298-309.
24. Kamada M, Suzuki K, Kato Y, et al. von Hippel-Lindau protein promotes the assembly of actin and vinculin and inhibits cells motility. Cancer Res 2001; 61: 4184-9.
25. Ohh M, Yauch RL, Lonergan KM, et al. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell 1998; 1: 959-68.
26. Koochekpur S, Jeffers M, Wang PH, et al. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphology in renal cell carcinoma cells. Mol Cell Biol 1999; 19: 5902-12.
27. Knebelmann B, Ananth S, Cohen HT, et al. Transforming growth factor α is a target for the von Hippel-Lindau tumor suppressor. Cancer Res 1998; 58: 226-31.
28. Ananth S, Knebelmann B, Gruning W, et al. Transforming growth factor β1 is a target for the von Hippel-Lindau tumor suppressor and a critical growth factor for clear cell carcinoma. Cancer Res 1999; 59: 2210-6.
29. Campbell LV, Gilbert E, Chamberlain CR, et al. Metastases of cancer to cancer. Cancer 1968; 22: 635-43.
30. Pasqualini R, Bourdoulous S, Koivunen E, et al. A polymeric form of fibronectin has antimetastatic effects against multiple tumor types. Nat Med 1996; 2: 1197-203.